ClinicalTrials.Veeva

Menu

A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition

Pfizer logo

Pfizer

Status and phase

Not yet enrolling
Phase 1

Conditions

Healthy Volunteers

Treatments

Drug: PF-07258669
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT07086664
2025-520763-41-00 (Registry Identifier)
C4541011

Details and patient eligibility

About

The purpose of this study is to look at safety, tolerability, and pharmacodynamic effects (i.e. how the study drug affects your body) of PF-07258669 in older participants ((60 years to <90 years) including those at risk of malnutrition.

The study medicine PF-07258669 is being developed for the treatment of unintended weight loss in older adults. People with this condition have decreased appetite and food intake, which is an important reason for poor nutrition and health results in people with unintended weight loss.

This is approximately a 26-week-long study with 9 visits to the study doctor and 4 telehealth visits (ie. visits by phone call). The study will include

  • Screening period for up to 4 weeks
  • Pre-treatment period of 2 weeks
  • Treatment period of 16 weeks : study drug (PF-07258669 or matching placebo)
  • Follow-up period of 4 weeks The study requires answering questionnaires and use of digital devices at home to measure blood pressure and physical activity. The study team will monitor how each participant is doing during the study

Enrollment

60 estimated patients

Sex

All

Ages

60 to 90 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Are 60 years to <90 years Are males or females who can no longer have children Have Body weight ≥40 kg and Body mass index (BMI) ≤25 kg/m2 Exclusion Criteria Evidence or history of clinically significant medical conditions. Positive for active, untreated HIV, hepatitis B, and/or hepatitis C History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.

Voluntary diet restriction or eating disorder

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

60 participants in 2 patient groups, including a placebo group

Placebo
Placebo Comparator group
Treatment:
Drug: Placebo
PF-07258669
Experimental group
Treatment:
Drug: PF-07258669

Trial contacts and locations

1

Loading...

Central trial contact

Pfizer CT.gov Call Center

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems